One of the most common side effects reported for all GLP-1R agonists is malaise ( 5 Future directions and summary As summarized previously, GLP-1R, and to some extent the peptide itself, influences the behavioral and neurochemical outcomes of alcohol and addictive drugs, such as nicotine, opioids, amphetamine, and cocaine
Drucker DJ (2024): Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Moreover, last year a separate study showed that 91% of obese individuals receiving a weekly dose of 15 mg Tirzepatidea recently developed GLP-1R/GIPR dual agonist, lost 5% of their body mass with 36% of participants on the same dosage losing at least 25% ( While these data are astoundingwith yearly progress in efficacy, we should consider that around 9% of patients receiving these game-changer treatments (Table 1)
Patients should work with registered dietitians to ensure adequate micronutrient intake, fiber consumption, and appropriate macronutrient distribution
Baseline weight, blood pressure, and heart rate should be documented
The studies on the benefits of microdosing are largely anecdotal
